PL3816164T3 - Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4 - Google Patents

Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4

Info

Publication number
PL3816164T3
PL3816164T3 PL19825725.5T PL19825725T PL3816164T3 PL 3816164 T3 PL3816164 T3 PL 3816164T3 PL 19825725 T PL19825725 T PL 19825725T PL 3816164 T3 PL3816164 T3 PL 3816164T3
Authority
PL
Poland
Prior art keywords
isothiazolo
pyrimidine compound
irak4 inhibitor
irak4
inhibitor
Prior art date
Application number
PL19825725.5T
Other languages
English (en)
Inventor
Yang Zhang
Jianfei Wang
Haizhong TAN
Jie Li
Jian Li
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Publication of PL3816164T3 publication Critical patent/PL3816164T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL19825725.5T 2018-06-25 2019-06-25 Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4 PL3816164T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810662580 2018-06-25
CN201910463156 2019-05-30
PCT/CN2019/092867 WO2020001449A1 (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Publications (1)

Publication Number Publication Date
PL3816164T3 true PL3816164T3 (pl) 2024-08-12

Family

ID=68986119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19825725.5T PL3816164T3 (pl) 2018-06-25 2019-06-25 Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4

Country Status (13)

Country Link
US (1) US11459337B2 (pl)
EP (1) EP3816164B9 (pl)
JP (1) JP7511489B2 (pl)
KR (1) KR20210024543A (pl)
CN (2) CN112243438B (pl)
AU (1) AU2019296118B2 (pl)
BR (1) BR112020026507A8 (pl)
CA (1) CA3104380A1 (pl)
DK (1) DK3816164T5 (pl)
ES (1) ES2978674T3 (pl)
HU (1) HUE066411T2 (pl)
PL (1) PL3816164T3 (pl)
WO (1) WO2020001449A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167676A1 (en) 2020-01-21 2021-07-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Irak4 inhibitor crystal and preparation method therefor
CN121398823A (zh) * 2023-04-21 2026-01-23 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类化合物治疗炎性疾病的用途
CN117164479A (zh) * 2023-08-21 2023-12-05 甘肃康巴斯生物科技有限公司 一种氨基乙腈盐酸盐的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
CN104902959A (zh) 2012-07-11 2015-09-09 林伯士艾瑞斯公司 Irak抑制剂和其用途
WO2015048281A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US10501437B2 (en) 2016-04-29 2019-12-10 Bayer Pharma Aktiengesellschaft Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
HUE064389T2 (hu) 2016-04-29 2024-03-28 Bayer Pharma AG Az N-{6-(2-hidroxipropán-2-il)-2-[2-(metilszulfonil)etil]-2h-indazol-5-il}-6- (trifluormetil)piridin-2-karboxamid polimorf formája
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase

Also Published As

Publication number Publication date
AU2019296118A8 (en) 2021-01-28
US11459337B2 (en) 2022-10-04
EP3816164A4 (en) 2022-03-16
JP7511489B2 (ja) 2024-07-05
JP2021529751A (ja) 2021-11-04
CA3104380A1 (en) 2020-01-02
WO2020001449A1 (zh) 2020-01-02
EP3816164B1 (en) 2024-04-03
KR20210024543A (ko) 2021-03-05
ES2978674T3 (es) 2024-09-17
US20210269459A1 (en) 2021-09-02
DK3816164T5 (da) 2024-07-22
BR112020026507A2 (pt) 2021-03-23
EP3816164A1 (en) 2021-05-05
CN112243438B (zh) 2022-03-15
EP3816164B9 (en) 2024-07-10
AU2019296118A1 (en) 2020-01-02
AU2019296118B2 (en) 2024-09-26
CN112243438A (zh) 2021-01-19
CN114716455A (zh) 2022-07-08
DK3816164T3 (da) 2024-04-22
BR112020026507A8 (pt) 2023-01-31
HUE066411T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
IL276802B1 (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
IL291471A (en) Pyrimido[3,2-d]pyrimidine compounds as immunomodulators
EP4037688A4 (en) ANTIVIRAL HETEROCYCLIC COMPOUNDS
IL288236A (en) 3,2-dihydroquinazoline compounds as inhibitors of nav1.8
SG11202104326TA (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL272262A (en) Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
IL282740B2 (en) 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-H1-pyrido[3,2-d]pyrimidine-2,4-dione
IL289233A (en) Compounds 4,4a,5,7,8,8a -hexapyrido[4,3-b][4-1]oxazin-3-one as magl inhibitors
IL284767A (en) Heterocyclic compounds as adenosine antagonists
IL290445A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
CA3275666A1 (en) Crystalline forms of the nrtti compound 4’-ethynyl-2-fluoro-2’- deoxyadenosine
IL284762A (en) Heterocyclic compounds as adenosine antagonists
HUE066411T2 (hu) Izotiazolo[5,4-d]pirimidin vegyület mint IRAK4 inhibitor
EP3831811A4 (en) HETEROCYCLIC COMPOUND
IL274963A (en) Thiano[2,3-d]pyrimidine compound with inhibitory activity for protein kinase
TN2017000065A1 (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
EP3878586A4 (en) LATHE
EP3801947B8 (en) Forming multi-tool
HK40077793A (en) Antiviral heterocyclic compounds
HK40064784A (en) Heterocyclic compounds as adenosine antagonists
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40055108A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors